Literature DB >> 2046109

Use of surveillance for invasive pneumococcal disease to estimate the size of the immunosuppressed HIV-infected population.

A Schuchat1, C V Broome, A Hightower, S J Costa, W Parkin.   

Abstract

We used population-based surveillance in New Jersey in 1986 to quantify the risk of invasive pneumococcal disease in persons with the acquired immunodeficiency syndrome (AIDS) and in those who went on to develop AIDS. Using pneumococcal surveillance, we also devised a method to estimate the size of the immunosuppressed population infected with the human immunodeficiency virus (HIV), the so-called pre-AIDS population. From rates of pneumococcal disease that occurred in areas with a low incidence of AIDS, we calculated the number of patients expected to contract pneumococcal disease in areas with a high incidence of AIDS. There were 59 more cases of pneumococcal disease observed than expected; 14 of these patients had AIDS by the time of pneumococcal infection. We attributed the remaining 45 cases to the increased risk of pneumococcal infection in pre-AIDS. The pre-AIDS pneumococcal cases and the attack rate of pneumococcal disease in pre-AIDS were used to estimate the size of the 1986 pre-AIDS New Jersey population as 8823 pre-AIDS cases (95% confidence interval, 7377 to 10,714) or 0.37% of the adult New Jersey population. Surveillance for marker diseases may provide a simple, independent method of estimating the pre-AIDS population.

Entities:  

Mesh:

Year:  1991        PMID: 2046109

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  8 in total

1.  Altered expression of Fc gammaRIII (CD16) on polymorphonuclear neutrophils from individuals with human immunodeficiency virus type 1 disease and pulmonary tuberculosis.

Authors:  S Meddows-Taylor; D J Martin; C T Tiemessen
Journal:  Clin Diagn Lab Immunol       Date:  1997-11

2.  Immune Responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination.

Authors:  M A Julie Westerink; Harry W Schroeder; Moon H Nahm
Journal:  Aging Dis       Date:  2011-07-20       Impact factor: 6.745

3.  Acute suppurative parotitis caused by Streptococcus pneumoniae in an HIV-infected man.

Authors:  Luis Guzman Vinasco; Sara Bares; Uriel Sandkovsky
Journal:  BMJ Case Rep       Date:  2015-03-02

4.  Depressed phagocytosis and oxidative burst in polymorphonuclear leukocytes from individuals with pulmonary tuberculosis with or without human immunodeficiency virus type 1 infection.

Authors:  S Shalekoff; C T Tiemessen; C M Gray; D J Martin
Journal:  Clin Diagn Lab Immunol       Date:  1998-01

5.  A cost-effectiveness analysis of pneumococcal vaccination in street-involved, HIV-infected patients.

Authors:  C A Marra; D M Patrick; F Marra
Journal:  Can J Public Health       Date:  2000 Sep-Oct

6.  Pneumococcal vaccine and HIV infection: report of a vaccine failure and reappraisal of its value in clinical practice.

Authors:  L J Willocks; K Vithayathil; A Tang; A Noone
Journal:  Genitourin Med       Date:  1995-04

Review 7.  Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals.

Authors:  Marta C Nunes; Shabir A Madhi
Journal:  Hum Vaccin Immunother       Date:  2012-02-01       Impact factor: 3.452

8.  COMMUNITY ACQUIRED PNEUMOCOCCAL PNEUMONIA IN NORTHWESTERN NIGERIA: EPIDEMIOLOGY, ANTIMICROBIAL RESISTANCE AND OUTCOME.

Authors:  Garba Iliyasu; Farouq Dayyab Mohammad; Abdulrazaq Garba Habib
Journal:  Afr J Infect Dis       Date:  2017-11-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.